Inflammation-associated depression: From serotonin to kynurenine

Psychoneuroendocrinology

Volumn 36, Issue 3, 2011, Pages 426-436

  Dantzer, Robert ^a   O'Connor, Jason C ^b   Lawson, Marcus A ^a   Kelley, Keith W ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Depression; Indoleamine 2,3 dioxygenase; Inflammation; Interferon alpha; Kynurenic acid; Kynurenine; Quinolinic acid; Tryptophane

Indexed keywords

3 HYDROXYKYNURENINE; ALPHA INTERFERON; ETANERCEPT; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; QUINOLINIC ACID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTHRALGIA; BIPOLAR DISORDER; CYTOKINE PRODUCTION; DEPRESSION; DRUG MECHANISM; ENZYME ACTIVATION; GENETIC POLYMORPHISM; HEPATITIS C; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; MELANCHOLIA; NEUROIMMUNOLOGY; NEUROPHARMACOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; QUASI EXPERIMENTAL STUDY; REVIEW; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; KYNURENINE; MODELS, BIOLOGICAL; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 79951960581     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.09.012     Document Type: Review

References (97)

1. Abe S., Hori T., Suzuki T., Baba A., Shiraishi H., Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem. Res. 1999, 24:359-363.
2. Ball H.J., Yuasa H.J., Austin C.J., Weiser S., Hunt N.H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 2009, 41:467-471.
3. Baran H., Kepplinger B., Draxler M. Endogenous kynurenine aminotransferases inhibitor is proposed to act as "glia depressing factor" (GDF). Int. J. Tryptophan Res. 2010, 3:13-22.
4. Baruch P., Filteau M.J., Bouchard R.H., Pourcher E., Vincent P., Jouvent R. The dimensional approach to clinical psychopharmacology: a polysemous concept. J. Psychiatry Neurosci. 1992, 17:55-60.
5. Benkelfat C., Ellenbogen M.A., Dean P., Palmour R.M., Young S.N. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch. Gen. Psychiatry 1994, 51:687-697.
6. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1920-1925.
7. Blasey C.M., Debattista C., Roe R., Block T., Belanoff J.K. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp. Clin. Trials 2009, 30:284-288.
8. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 2002, 22:86-90.
9. Bremmer M.A., Beekman A.T., Deeg D.J., Penninx B.W., Dik M.G., et al. Inflammatory markers in late-life depression: results from a population-based study. J. Affect Disord. 2008, 106:249-255.
10. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
11. Capuron L., Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 2003, 17(Suppl 1):S119-S124.
12. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
13. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., et al. Interferon-alpha-induced changes in tryptophan metabolism relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
14. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol. Psychiatry 2005, 58:190-196.
15. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
16. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 2003, 160:1342-1345.
17. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alpha therapy by the patient's initial affective state. N. Engl. J. Med. 1999, 340:1370.
18. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol. 2000, 18:2143-2151.
19. Capuron L., Ravaud A., Miller A.H., Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav. Immun. 2004, 18:205-213.
20. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
21. Curzon G., Bridges P.K. Tryptophan metabolism in depression. J. Neurol. Neurosurg. Psychiatry 1970, 33:698-704.
22. Dantzer R., Capuron L., Irwin M.R., Miller A.H., Ollat H., et al. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008, 33:18-29.
23. Dantzer R., Kelley K.W. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci. 1989, 44:1995-2008.
24. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
25. De La Garza R., Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:781-792.
26. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv. Exp. Med. Biol. 1999, 461:117-127.
27. Dunn A.L., Crnic L.S. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav. Immun. 1993, 7:104-111.
28. Eisenberger N.I., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage 2009, 47:881-890.
29. Fahey B., Hickey B., Kelleher D., O'Dwyer A.M., O'Mara S.M. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behav. Brain Res. 2007, 182:80-87.
30. Frasure-Smith N., Lesperance F., Irwin M.R., Sauve C., Lesperance J., Theroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol. Psychiatry 2007, 62:302-308.
31. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
32. Fuchs D., Moller A.A., Reibnegger G., Stockle E., Werner E.R., Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 1990, 3:873-876.
33. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J. Child Psychol. Psychiatry 2000, 51:935-943.
34. Godbout J.P., Moreau M., Lestage J., Chen J., Sparkman N.L., et al. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008, 33:2341-2351.
35. Guillemin G.J., Cullen K.M., Lim C.K., Smythe G.A., Garner B., et al. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 2007, 27:12884-12892.
36. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414.
37. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115(Pt 5):1249-1273.
38. Irwin M. Immune correlates of depression. Adv. Exp. Med. Biol. 1999, 461:1-24.
39. Irwin M.R., Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 2007, 21:374-383.
40. Joynt K.E., Whellan D.J., O'Connor C.M. Depression and cardiovascular disease: mechanisms of interaction. Biol. Psychiatry 2003, 54:248-261.
41. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berlin) 2000, 152:383-389.
42. Kanai M., Nakamura T., Funakoshi H. Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci. Res. 2009, 64:111-117.
43. Katafuchi T., Kondo T., Take S., Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann. N.Y. Acad. Sci. 2006, 1088:230-237.
44. Kentner A.C., Miguelez M., James J.S., Bielajew C. Behavioral and physiological effects of a single injection of rat interferon-alpha on male Sprague-Dawley rats: a long-term evaluation. Brain Res. 2006, 1095:96-106.
45. Kiecolt-Glaser J.K., Glaser R. Depression and immune function: central pathways to morbidity and mortality. J. Psychosom. Res. 2002, 53:873-876.
46. Kling M.A., Coleman V.H., Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress. Anxiety 2009, 26:641-649.
47. Kohl C., Walch T., Huber R., Kemmler G., Neurauter G., et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J. Affect Disord. 2005, 86:135-142.
48. Lesperance F., Frasure-Smith N. Depression and heart disease. Cleve Clin. J. Med. 2007, 74(Suppl. 1):S63-S66.
49. Lestage J., Verrier D., Palin K., Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav. Immun. 2002, 16:596-601.
50. Lob S., Konigsrainer A., Schafer R., Rammensee H.G., Opelz G., Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008, 111:2152-2154.
51. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31:1289-1294.
52. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 2009, 65:344-348.
53. Mackay G.M., Forrest C.M., Christofides J., Bridel M.A., Mitchell S., et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin. Exp. Pharmacol. Physiol. 2009, 36:425-435.
54. Maes M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 1999, 461:25-46.
55. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995, 20:111-116.
56. Maes M., Verkerk R., Bonaccorso S., Ombelet W., Bosmans E., Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 2002, 71:1837-1848.
57. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 1999, 461:75-81.
58. Milaneschi Y., Corsi A.M., Penninx B.W., Bandinelli S., Guralnik J.M., Ferrucci L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol. Psychiatry 2009, 65:973-978.
59. Miller A.H. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2008, 23:149-158.
60. Miller A.H. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2009, 23:149-158.
61. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074:25-37.
62. Moller S.E., Kirk L., Honore P. Tryptophan tolerance and metabolism in endogenous depression. Psychopharmacology (Berlin) 1982, 76:79-83.
63. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology 2000, 23:601-622.
64. Moreau M., Andre C., O'Connor J.C., Dumich S.A., Woods J.A., et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav. Immun. 2008, 22:1087-1095.
65. Moreau M., Lestage J., Verrier D., Mormede C., Kelley K.W., et al. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J. Infect. Dis. 2005, 192:537-544.
66. Muller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):97-106.
67. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11:680-684.
68. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61:519-525.
69. Myint A.M., Kim Y.K., Verkerk R., Park S.H., Scharpe S., et al. Tryptophan breakdown pathway in bipolar mania. J. Affect Disord. 2007, 102:65-72.
70. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect Disord. 2007, 98:143-151.
71. Myint A.M., O'Mahony S., Kubera M., Kim Y.K., Kenny C., et al. Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. J. Psychopharmacol. 2007, 21:843-850.
72. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 2009, 29:4200-4209.
73. O'Connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212.
74. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
75. O'Connor M.F., Irwin M.R., Wellisch D.K. When grief heats up: pro-inflammatory cytokines predict regional brain activation. Neuroimage 2009, 47:891-896.
76. Olsson S.K., Samuelsson M., Saetre P., Lindstrom L., Jonsson E.G., et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010, 35:195-199.
77. Penninx B.W., Kritchevsky S.B., Yaffe K., Newman A.B., Simonsick E.M., et al. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 2003, 54:566-572.
78. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 2009, 23:1109-1116.
79. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
80. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58:445-452.
81. Riedel W.J., Klaassen T., Schmitt J.A. Tryptophan, mood, and cognitive function. Brain Behav. Immun. 2002, 16:581-589.
82. Schrocksnadel K., Widner B., Bergant A., Neurauter G., Schennach H., et al. Longitudinal study of tryptophan degradation during and after pregnancy. Life Sci. 2003, 72:785-793.
83. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 2004, 4:12-17.
84. Scrandis D.A., Langenberg P., Tonelli L.H., Sheikh T.M., Manogura A.C., et al. Prepartum depressive symptoms correlate positively with C-reactive protein levels and negatively with tryptophan levels: a preliminary report. Int. J. Child Health Hum. Dev. 2008, 1:167-174.
85. Smith R.S. The macrophage theory of depression. Med. Hypotheses 1991, 35:298-306.
86. Strike P.C., Wardle J., Steptoe A. Mild acute inflammatory stimulation induces transient negative mood. J. Psychosom. Res. 2004, 57:189-194.
87. Ting K.K., Brew B., Guillemin G. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox. Res. 2007, 12:247-262.
88. Tsao C.W., Lin Y.S., Cheng J.T., Chang W.W., Chen C.L., et al. Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand. J. Immunol. 2006, 63:106-115.
89. Tsao C.W., Lin Y.S., Cheng J.T., Lin C.F., Wu H.T., et al. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J. Psychopharmacol. 2008, 22:753-760.
90. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
91. Van der Does A.J. The effects of tryptophan depletion on mood and psychiatric symptoms. J. Affect Disord. 2001, 64:107-119.
92. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10:538-544.
93. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression-what is the link? Brain Behav. Immun. 2002, 16:590-595.
94. Wolf J.M., Rohleder N., Bierhaus A., Nawroth P.P., Kirschbaum C. Determinants of the NF-kappaB response to acute psychosocial stress in humans. Brain Behav. Immun. 2009, 23:742-749.
95. Wright C.E., Strike P.C., Brydon L., Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav. Immun. 2005, 19:345-350.
96. Yuasa H.J., Ball H.J., Austin C.J., Hunt N.H. 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2010, 157:10-15.
97. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.